Brief: Merck - Pimicotinib Treatment Demonstrates Deep And Durable Tumor Responses And Continued Improvements In Pain And Function For Patients With Tgct

Merck KGaA

17/10/2025 15:03

Oct 17 (Reuters) - MERCK KGAA MRCG.DE:

PIMICOTINIB TREATMENT DEMONSTRATES DEEP AND DURABLE TUMOR RESPONSES AND CONTINUED IMPROVEMENTS IN PAIN AND FUNCTION FOR PATIENTS WITH TGCT

WITH MEDIAN FOLLOW-UP OF 14.3 MONTHS, PIMICOTINIB DEMONSTRATED INCREASING ORR OVER TIME, FROM 54% AT WEEK 25 TO 76.2%

GLOBAL PHASE 3 MANEUVER STUDY DEMONSTRATED ONGOING IMPROVEMENTS IN KEY SECONDARY ENDPOINTS INCLUDING PAIN AND FUNCTION

APPLICATION FOR MARKETING AUTHORIZATION UNDER REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA), WITH ADDITIONAL APPLICATIONS PLANNED IN THE U.S. AND OTHER MARKETS

Further company coverage: MRCG.DE

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))